Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as apomorphine infusion
Onapgo (SPN-830) · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Apomorphine infusion | EXPERIMENTAL | Continuous subcutaneous apomorphine infusion |
| Name | Type | Description |
|---|---|---|
| apomorphine infusion | DRUG | Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device |
Inclusion Criteria: * Advanced idiopathic PD consistent with UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria * Overall motor control is unsatisfactory in the opinion of the Investigator and subject despite optimized treatment with available therapies, which must include a sta...
Onapgo (SPN-830) is being developed for the treatment of idiopathic Parkinson's disease. It is an apomorphine infusion therapy, meaning it delivers apomorphine continuously under the skin. It is intended for patients with Parkinson's disease, though its exact place in therapy is still under study in clinical trials.
Onapgo (SPN-830) is being developed by Supernus Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker SUPN. Supernus is a specialty pharmaceutical company focused on central nervous system disorders, and it is advancing Onapgo as a potential treatment for idiopathic Parkinson's disease.
Onapgo (SPN-830) is in Phase 3 clinical development. The ongoing trial is a Phase 3 long-term safety study of apomorphine infusion in patients with idiopathic Parkinson's disease. The program has not yet completed its clinical development, and the drug remains investigational.
Onapgo (SPN-830) is being evaluated in a single Phase 3 trial, NCT02339064, titled "Infusion of Apomorphine: Long-term Safety Study." The trial is active but not recruiting, has enrolled 99 participants, and is being conducted in the United States. It is an uncontrolled, open-label study in adults with idiopathic Parkinson's disease.
Yes, Onapgo is also known as apomorphine infusion. SPN-830 is the development code for this formulation, which delivers apomorphine by continuous subcutaneous infusion. Apomorphine is a small molecule used in Parkinson's disease, and Onapgo refers specifically to the infusion product being developed by Supernus Pharmaceuticals.